Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis Source: Eur Respir J 2003; 22: Suppl. 45, 430s Year: 2003
A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
A comparison of nebulized budesonide, intramuscular and oral dexamethasone in the treatment of croup among children aged 6-36 months Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013
Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Presence of fungus in sputum of patients treated with antibiotics or inhaled steroids Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas Year: 2010
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020 Year: 2020
Effects of switching inhaled medication from twice a day to once a day in patients with bronchial asthma Source: International Congress 2016 – Asthma points to ponder Year: 2016
The effect of heparin nebulization on BAL cellularity and clinical evaluation in a long-time study in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002
Bacterial profile and antibiotic susceptibility from patients with exacerbation of COPD: 10 – years prospective study Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
A preliminary study to identify correlations between blood glucose levels and cardiorespiratory observations in acute asthma patients receiving nebulised salbutamol. Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Inhaled dry powder mannitol in cystic fibrosis (CF): Microbiology results from the 6 month double-blind CF301 study Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Changes in sputum composition during 15 minutes of sputum induction in asthmatic and COPD subjects Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Salt chamber treatment does not affect induced sputum inflammatory markers in asthma patients treated with inhaled steroids Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
A randomized crossover study of sputum induction by physiotherapy and hypertonic saline techniques in asthmatic children Source: International Congress 2017 – Diagnostic tools and comorbidities in paediatric asthma Year: 2017
Does omalizumab attenuate blood eosinophilia at 52 weeks; a single centre observation Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004